RxDoctor Payments Data

Minh Huynh, MD

Internal Medicine · San Jose, CANPI 1063437309

Payments from drug & device makers

$1,528in general payments, 2019–2025

Across 58 payments — averaging $26.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$301
  • AbbVie$248
  • AstraZeneca$220
  • GSK$168
  • Boehringer Ingelheim$167
  • Boston Scientific$125
  • plus $299 from 8 others

What the payments were for

  • Food & beverage$1,41092%
  • Education$1188%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,528 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$137,548
Medicare patients
212
Services billed
1,803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin623$524,001
JanuviaSitagliptin Phosphate205$145,403
VascepaIcosapent Ethyl253$113,568
Icosapent Ethyl283$103,066
CreonLipase/Protease/Amylase60$63,391
EliquisApixaban51$53,386
FarxigaDapagliflozin Propanediol36$31,809
XareltoRivaroxaban28$30,697
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$24,334
RybelsusSemaglutide16$21,403
Omega-3 Acid Ethyl Esters313$15,770
Albuterol Sulfate HfaAlbuterol Sulfate391$15,741
Atorvastatin Calcium1,395$15,075
TradjentaLinagliptin21$14,298
Qvar RedihalerBeclomethasone Dipropionate49$13,148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$167$547,880664 claims
AbbVieCreon$248$63,39160 claims
AstraZenecaFarxiga$220$31,80936 claims
GSKTrelegy Ellipta, Shingrix$168$29,95266 claims
Novo NordiskRybelsus$42$21,40316 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$116$13,14849 claims
Aimmune Therapeutics, Inc.Zenpep$29$4,89211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →